Today's Rundown Can Bristol-Myers' Opdivo-Yervoy pairing be 'practice-changing' in first-line NSCLC? Experts disagree Amgen KRAS colon cancer data disappoint Merck's Keytruda posts first-in-class victory in pre-surgery breast cancer AbbVie's PARP inhibitor veliparib finally gets a win, but can it compete? Glaxo sizes up AZ, Merck challenge with Zejula's all-comers ovarian cancer win Grail's multi-cancer blood test expands data in over 20 disease types AZ, Merck's Lynparza chases Avastin combo nod with big ovarian cancer win Astellas, Seattle Genetics' Keytruda combo shrinks 71% of bladder cancers Lilly's Verzenio looks for an edge with gold-standard data in tough-to-treat patients G1 shares data on significant increase in breast cancer survival Novartis' Kisqali again shows it helps breast cancer patients live longer. Will doctors listen? Lilly's RET drug shrinks more than half of rare thyroid cancers AstraZeneca eyes payer boost with Tagrisso's latest survival win Merck learns from Keytruda's monotherapy miss in triple-negative breast cancer Featured Story | | | Saturday, September 28, 2019 Merck & Co.’s Keytruda may have the chemo-combo business locked up in previously untreated lung cancer, but Bristol-Myers Squibb figures it has a chance to bring in patients who prefer to skip chemo and use a second immunotherapy instead. Its Opdivo-Yervoy combo cut death risk by 21% in a showing that could finally get the company into the first-line NSCLC business. |
|
|---|
|
Top Stories Saturday, September 28, 2019 In lung cancer, Amgen’s buzzy KRAS drug hit the heights. But in its latest update, it didn't follow suit in colon cancer. Amgen was testing its drug in an early-stage, phase 1 focused on patients with previously treated KRAS G12C-mutant solid tumors. Sunday, September 29, 2019 Merck’s Keytruda may have come up short in metastatic triple-negative breast cancer over the weekend, but in the pre-surgery setting, it posted a first-of its-kind win. Among pre-surgery patients, the combination of Keytruda and chemo beat out solo chemo at spurring pathological complete responses. Sunday, September 29, 2019 BARCELONA—Quietly, and without the fanfare of gene and cell therapies, PARP inhibitors from the likes of AstraZeneca, Merck and GlaxoSmithKline/Tesaro have been racking up big trial wins in breast and ovarian cancers. Saturday, September 28, 2019 GlaxoSmithKline wanted to prove Zejula could keep ovarian cancer at bay in all women after initial chemotherapy, not just those with BRCA mutations. And it did: The PARP inhibitor cut the risk of progression by 38% across the study, and more than half in a key patient group. Will the numbers be enough to tackle market leader Lynparza? Saturday, September 28, 2019 Grail has taken a few more steps forward in its quest to develop a diagnostic test capable of not only spotting cancer in its earliest stages, but also identifying its location within the body using markers taken from the bloodstream. Saturday, September 28, 2019 Right now, Roche’s Avastin is the go-to therapy for keeping ovarian cancer from progressing in patients without a BRCA mutation who have received an initial round of chemo. But with their latest combo data, AstraZeneca and Merck are hoping to get Lynparza in on that market. Saturday, September 28, 2019 Astellas and Seattle Genetics’ antibody-drug conjugate is at it again. On Saturday, the duo revealed data showing enfortumab vedotin paired with Merck’s Keytruda shrank 71% of tumors and wiped out 13% of them in previously untreated patients with advanced urothelial cancer Sunday, September 29, 2019 It’s tough to be a third-to-market drug, particularly when you’re trailing a first-up launch like Pfizer’s blockbuster Ibrance. But with some new data showing Verzenio can help tough-to-treat breast cancer patients live significantly longer, Eli Lilly’s hoping for a kick-start for its contender. Saturday, September 28, 2019 G1 Therapeutics has linked the addition of trilaciclib to chemotherapy to improved overall survival in triple-negative breast cancer patients. People who received the CDK4/6 inhibitor lived 20.1 months, on average. Sunday, September 29, 2019 Novartis and its breast cancer drug Kisqali won approval two years behind Pfizer’s Ibrance, and it’s lagging even farther behind in terms of sales. But the Swiss drugmaker now has new data it hopes can help close that yawning gap. Sunday, September 29, 2019 The RET inhibitor Eli Lilly picked up in its Loxo Oncology buyout continues to deliver. On the heels of an encouraging performance in lung cancer, the drug shrank tumors in more than half of patients with a rare thyroid cancer who had already tried at least two kinase inhibitors. Saturday, September 28, 2019 AstraZeneca’s Tagrisso is already rolling in EGFR-mutated lung cancer, but new survival data could help spur additional reimbursement. Saturday at the European Society for Medical Oncology annual meeting, the British drugmaker touted results showing that using Tagrisso instead of older TKI inhibitors could cut patients’ risk of death by 20%. Saturday, September 28, 2019 It’s official: Merck won’t be stepping on Roche’s toes anytime soon when it comes to metastatic triple negative breast cancer. But from its failed phase 3 trial, the New Jersey drugmaker did take away some important findings, execs say. For one, positive effects of treatment with Merck's Keytruda increased as patients’ levels of biomarker PD-L1 increased. Resources Sponsored by: Life Image The time has finally come when medical imaging can be effectively utilized into the RWE process. Read the whitepaper on the best practices for incorporating Real World Imaging.™ Sponsored by: Signals Analytics A new report from Signals Analytics: 36 million people worldwide are affected by Alzheimer’s. What’s the future outlook of emerging treatments and early disease diagnostics? Download the report. Sponsored by: Patheon, by Thermo Fisher Scientific Is your API development on track? Sponsored by: Roche and IQVIA A global landscape study of funding trends and innovations. Sponsored by: Reprints Desk, Inc. Slashing your R&D costs is easier than you think. Sponsored by: BioAnalytix, Inc. Download the White Paper and learn how detailed characterization can guide successful development of gene therapy products. Sponsored by: ON24 Compare digital program performance and audience engagement among your life sciences peers. Sponsored by: Decision Resources Group Clinically Integrated Networks are vehicles for powerful IDNs to extend their influence into the physician sector and play a key role for IDNs trying to pave a path to becoming a self-contained healthcare ecosystem. Sponsored by: Blue Matter, strategic consultants in the life sciences White paper providing an overview of precision medicine in oncology, as well as a look ahead at future developments and keys to success for pharmaceutical and diagnostics companies. Sponsored by: Catalent Pharma Solutions Download the executive summary to learn about manufacturing strategies for these expedited programs where there might be just one chance to get it right. Sponsored by: WEGO Health Patient influencers on social platforms like Facebook, Instagram and Twitter are driving high-value actions for brands, and pharma is no exception. Download our report to discover how influencers will help you boost brand trust and best practices for working with influencers. Sponsored by: Vineti Developing a cell therapy, gene therapy, or personalized cancer vaccine? Modern data management makes a critical difference in operational and regulatory outcomes. This whitepaper will help your team leverage the latest data strategies for success. Sponsored by: AlphaSense AI-powered research tools are making it easier to source confident healthcare market intelligence with accuracy and efficiency -- download now to learn more about improving your competitive research strategy. Sponsored by: Elemental Machines Your lab is talking to you, are you listening? Sponsored by: Recro Gainesville Vetting CDMOs but unsure what to look for in prospective partners’ multiproduct facilities? Sponsored by: Baxter BioPharma Solutions Check out Baxter BioPharma Solutions’ whitepaper to learn considerations and options for developing a product in a prefilled syringe. Sponsored by: Catalent Catalent has a proven history of successful technology transfers and over 165 product launched annually. We offer integrated development, analytical, clinical supply, and clinical and commercial manufacturing between our network of sites. Sponsored by: Catalent This presentation discusses how to manage stability challenges for accelerated approval programs, fit-for-purpose manufacturing strategies, overcoming scale-up challenges, developing a comprehensive solution for unexpected challenges, and avoiding typical pitfalls in accelerated programs. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Medical Affairs Strategic Summit (MASS) West 2019 September 23 - September 25, 2019 | San Diego, CA U.S. Healthcare Compliance Certificate Program October 14-17, 2019 | Newark, New Jersey European Healthcare Compliance Certificate Program October 21-25, 2019 | Paris, France 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA | 